CN108348600A - 治疗自身免疫病症和同种免疫病症的方法 - Google Patents

治疗自身免疫病症和同种免疫病症的方法 Download PDF

Info

Publication number
CN108348600A
CN108348600A CN201680044603.9A CN201680044603A CN108348600A CN 108348600 A CN108348600 A CN 108348600A CN 201680044603 A CN201680044603 A CN 201680044603A CN 108348600 A CN108348600 A CN 108348600A
Authority
CN
China
Prior art keywords
antibody
amino acid
acid sequence
variable region
include amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680044603.9A
Other languages
English (en)
Chinese (zh)
Inventor
格雷汉姆·帕里
帕维尔·A·尼基廷
桑迪普·帕尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biobelli America
Original Assignee
Biobelli America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biobelli America filed Critical Biobelli America
Publication of CN108348600A publication Critical patent/CN108348600A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680044603.9A 2015-06-26 2016-06-23 治疗自身免疫病症和同种免疫病症的方法 Pending CN108348600A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
US62/185,362 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (1)

Publication Number Publication Date
CN108348600A true CN108348600A (zh) 2018-07-31

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680044603.9A Pending CN108348600A (zh) 2015-06-26 2016-06-23 治疗自身免疫病症和同种免疫病症的方法

Country Status (12)

Country Link
US (3) US20180169240A1 (enExample)
EP (1) EP3313417A4 (enExample)
JP (1) JP6963509B2 (enExample)
KR (1) KR20180020296A (enExample)
CN (1) CN108348600A (enExample)
AU (2) AU2016282782A1 (enExample)
CA (1) CA2990662A1 (enExample)
EA (1) EA038567B1 (enExample)
HK (1) HK1254030A1 (enExample)
IL (1) IL256424B2 (enExample)
MX (2) MX2017016835A (enExample)
WO (1) WO2016210172A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069606A (zh) * 2016-04-29 2018-12-21 辉瑞大药厂 干扰素β抗体及其用途
CN114829604A (zh) * 2019-10-16 2022-07-29 中外制药株式会社 抗体、药物组合物和方法
CN116724236A (zh) * 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use
US12473353B2 (en) 2019-05-15 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule, a pharmaceutical composition, and a method

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
HK1259251A1 (zh) 2015-04-06 2019-11-29 Bioverativ Usa Inc. 人源化抗c1s抗体及其使用方法
MY198182A (en) 2016-10-12 2023-08-09 Bioverativ Usa Inc Anti-C1s Antibodies and Methods of use Thereof
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079174A1 (en) * 1999-08-23 2005-04-14 Biocrystal, Ltd. Methods and compositions for immunotherapy of B cell involvement in promotion of a disease condition comprising multiple sclerosis
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US8877197B2 (en) * 2012-11-02 2014-11-04 True North Therapeutics, Inc. Anti-complement C1s

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538384A (en) * 2002-09-06 2009-04-30 Alexion Pharma Inc Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
EP2283355A2 (en) * 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20110002931A1 (en) * 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079174A1 (en) * 1999-08-23 2005-04-14 Biocrystal, Ltd. Methods and compositions for immunotherapy of B cell involvement in promotion of a disease condition comprising multiple sclerosis
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US8877197B2 (en) * 2012-11-02 2014-11-04 True North Therapeutics, Inc. Anti-complement C1s

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王文勇: "《免疫细胞（组织）化学和分子病理学技术》", 30 November 2010, 西安：第四军医大学出版社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069606A (zh) * 2016-04-29 2018-12-21 辉瑞大药厂 干扰素β抗体及其用途
US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use
US12473353B2 (en) 2019-05-15 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule, a pharmaceutical composition, and a method
CN114829604A (zh) * 2019-10-16 2022-07-29 中外制药株式会社 抗体、药物组合物和方法
CN116724236A (zh) * 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳

Also Published As

Publication number Publication date
US20250295768A1 (en) 2025-09-25
MX2023002021A (es) 2023-03-15
HK1254030A1 (zh) 2019-07-12
US20220249664A1 (en) 2022-08-11
AU2022215307A1 (en) 2022-09-08
EA038567B1 (ru) 2021-09-15
EP3313417A4 (en) 2019-06-12
NZ738570A (en) 2025-05-02
IL256424A (en) 2018-02-28
WO2016210172A1 (en) 2016-12-29
AU2022215307B2 (en) 2025-09-04
IL256424B1 (en) 2024-05-01
KR20180020296A (ko) 2018-02-27
JP6963509B2 (ja) 2021-11-10
CA2990662A1 (en) 2016-12-29
AU2016282782A1 (en) 2018-01-18
BR112017027578A2 (pt) 2018-08-28
US20180169240A1 (en) 2018-06-21
JP2018526330A (ja) 2018-09-13
EA201890106A1 (ru) 2018-05-31
IL256424B2 (en) 2024-09-01
EP3313417A1 (en) 2018-05-02
MX2017016835A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
US20250295768A1 (en) Methods of treating autoimmune and alloimmune disorders
AU2019246821B2 (en) Anti-cd40 antibodies and uses thereof
CN106554417B (zh) 抗ox40抗体和使用其的方法
CN103946238B (zh) 抗ox40抗体及使用其的方法
US9115195B2 (en) Therapeutic DLL4 binding proteins
JP5782132B2 (ja) 抗ＣＤ４０抗体のサイレントＦｃ変異体
US9475872B2 (en) Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
US10875916B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
PT2426150T (pt) Anticorpos anti-nkg2a e utilizações dos mesmos
TW201138825A (en) TNF-α binding proteins
CN108779171A (zh) 抗补体因子c1q的fab片段及其应用
TW201211063A (en) Humanized anti-factor D antibodies and uses thereof
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
WO2020007240A1 (zh) 一种双特异性抗体及其用途
TW201902925A (zh) 抗cd40抗體、其抗原結合片段及其醫藥用途
CN116724236A (zh) 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
CA2824313A1 (en) Tlr3 binding agents
BR122024005916A2 (pt) Uso de um anticorpo que se liga especificamente ao componente 1s (c1s) do complemento no tratamento de distúrbios autoimunes
BR112017027578B1 (pt) Método in vitro de monitoramento da eficácia de um método de tratamento que compreende administrar um anticorpo anti-c1s
RU2816994C2 (ru) Антитела к bcma, содержащие только тяжелую цепь
JP2025516140A (ja) インターロイキン－１９を標的とする抗体及び方法
CN119907812A (zh) 靶向λ亚类免疫球蛋白轻链构象特异性表位的单克隆抗体
EA040553B1 (ru) Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259259

Country of ref document: HK